KCM
BLRX

Kennedy Capital Management’s BioLineRX BLRX Stock Holding History

Kennedy Capital Management’s Portfolio BLRX Stock Details BLRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-17,389
Closed -$1.14M – 670
2020
Q3 		$1.14M Buy
+17,389
New +$1.31M 0.03% 534

Other funds holding BLRX

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
PHP
Parkman Healthcare Partners Stamford, Connecticut $970M AUM 79.46% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
PVH
Psagot Value Holdings Tel Aviv, Israel $11M AUM 32.09% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return
SFI
Susquehanna Fundamental Investments Bala Cynwyd, Pennsylvania $2.67B AUM 21.74% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return
CCB
Cutter & Co Brokerage Ballwin, Missouri $423M AUM 15.02% 1-Year Est. Return
TNB
Thomasville National Bank Thomasville, Georgia $1.82B AUM

Kennedy Capital Management's BLRX Position: Q4 2020 in Review

Kennedy Capital Management sold out of BioLineRX (BLRX) in Q4 2020, closing a stake of 17,389 shares — an estimated $1.14M sold.

Kennedy Capital Management first reported a position in BLRX in Q3 2020 and held it in 1 quarter. The position peaked at $1.14M in Q3 2020. 21 funds tracked by Wall St. Rank hold BLRX as of Q4 2020.

  • Kennedy Capital Management reported no remaining BioLineRX position as of Q4 2020 after selling out during the quarter.
  • Kennedy Capital Management sold 17,389 BioLineRX shares in Q4 2020, an estimated $1.14M.
  • Kennedy Capital Management first reported a position in BioLineRX in Q3 2020 and held it in 1 quarter.
  • Kennedy Capital Management's BioLineRX position peaked at $1.14M in Q3 2020.
  • 21 funds tracked by Wall St. Rank held BioLineRX as of Q4 2020.

Based on Kennedy Capital Management's 13F filing for Q4 2020, filed 12 Feb 2021.